Non-dilutive funding can be a game-changer for biotech companies, providing vital resources without diluting equity. What are the main sources of non-dilutive funding across Europe? What are the latest changes in grant financing, eligibility criteria, application processes? Are there specific funding opportunities or programs that are gaining traction in Europe, and what sectors or areas do they target? What are the key considerations and best practices for preparing successful grant applications? In which situations should non-dilutive funding be preferred? How to evaluate the potential impact of non-dilutive funding on business strategies and future growth?
Moderator: Jeroen Schuermans, Grant consultant, Akkodis 
